丹麦、瑞典和挪威新诊断、持续性及慢性免疫性血小板减少症患者在日常临床实践中对罗米司亭的血小板反应
研究纳入2009-2018年丹麦、瑞典和挪威285例ITP持续≥6个月且接受罗米司亭治疗的成人患者,按病程分为新诊断(<3个月)、持续性(3-12个月)和慢性(>12个月)亚组,比较启动罗米司亭时的特征、剂量及持久血小板反应(14-24周内≥75%的测量值≥50×10⁹/L)。新诊断组较长期病程组ITP更严重、持久血小板反应频率更高、停药后中位血小板计数更高。
要点
- 285例罗米司亭启动者中新诊断81例(28%)、持续性47例(16%)、慢性157例(55%)。
- 持久血小板反应在新诊断、持续性和慢性ITP中分别为64.6%、52.9%和52.7%。
- 停药后中位血小板计数在新诊断、持续性和慢性ITP中分别为138×10⁹/L、68×10⁹/L和71×10⁹/L。
核心结论
- 与罗米司亭启动时病程较长的患者相比,新诊断患者ITP更严重、持久血小板反应频率更高、停药后中位血小板计数更高。
研究设计与样本
- 在丹麦、瑞典和挪威2009-2018年期间,纳入ITP持续≥6个月且接受罗米司亭治疗的成人患者,按启动罗米司亭时病程分为新诊断(<3个月)、持续性(3-12个月)和慢性(>12个月)亚组,共285例罗米司亭启动者。
主要发现
- 新诊断ITP患者较病程更长者更多具有低合并症水平、两种及以上既往ITP治疗和既往需住院的出血。
- 各亚组中位罗米司亭剂量相似。
- 治疗期间各亚组中位血小板计数相似(75-76×10⁹/L)。
- 持久血小板反应在新诊断、持续性和慢性ITP中分别为64.6%、52.9%和52.7%。
- 停药后中位血小板计数在新诊断、持续性和慢性ITP中分别为138×10⁹/L、68×10⁹/L和71×10⁹/L。
关键数值与推荐
- 持久血小板反应定义为14-24周内≥75%的测量值≥50×10⁹/L。
- 285例罗米司亭启动者中新诊断81例(28%)、持续性47例(16%)、慢性157例(55%)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patient characteristics and platelet responses at romiplostim initiation according to the duration of immune thrombocytopenia (ITP) are poorly understood. Amongst romiplostim-exposed adults with ITP lasting ≥6 months during 2009-2018 in Denmark, Sweden, and Norway, we examined characteristics at romiplostim initiation, romiplostim dosage, and durable platelet response (≥75% of measurements ≥50 × 109/L at 14-24 weeks) for subcohorts with newly diagnosed (duration <3 months), persistent (3-12 months), or chronic (>12 months) ITP initiating romiplostim. The 285 romiplostim initiators comprised 81 (28%) with newly diagnosed, 47 (16%) with persistent, and 157 (55%) with chronic ITP. More patients with newly diagnosed ITP than longer ITP duration, had low comorbidity levels, two or more prior ITP therapies, and previous bleeding requiring hospitalisation. The median romiplostim doses were similar across subcohorts. During treatment, median platelet counts were similar across subcohorts (75-76 × 109/L), and the durable platelet response was 64.6%, 52.9%, and 52.7% for newly diagnosed, persistent, and chronic ITP, respectively. After treatment cessation, the median platelet count was 138 × 109/L, 68 × 109/L, and 71 × 109/L, respectively. In conclusion, newly diagnosed patients, compared with romiplostim initiators with longer disease duration, had more severe ITP, higher frequency of durable platelet response, and higher median platelet count after cessation.
引用
- Christiansen CF, Risbo N, Ghanima W, et al. Platelet response to romiplostim amongst patients with newly diagnosed, persistent, and chronic immune thrombocytopenia in routine clinical practice in Denmark, Sweden, and Norway. Br J Haematol. 2024. PMID: 39102877. doi:10.1111/bjh.19688
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。